Please login to the form below
Advent
This page shows the latest Advent news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s flat sales focus investor attention on M&A
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
Latest news
-
P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
-
Sanofi sells European generics to Advent for $2.4bn
The deal will create a new, independent European generics company. Private equity group Advent has agreed a 1.9bn ($2.4bn) deal to buy the European generics unit of French pharma ... Sanofi has been looking to divest the Zentiva generics unit since 2016
-
Time running out on new Stada takeover bid
That offer beat out a rival overture from Advent and Permira.
-
Trouble at the top of Stada as Bain and Cinven mull fresh bid
Their offer beat out another bid from Advent and Permira.
-
No deal for Stada as private equity takeover bid collapses
Stada's board had lent its support to the Bain-Cinven offer over a rival 58 per share bid from Advent and Permira.
More from news
Approximately 3 fully matching, plus 91 partially matching documents found.
Latest Intelligence
-
Behaviour change: what is the buzz all about?
The advent of the ‘informed patient’ for whom social media, in particular, has provided a voice, means that patients have become more central – a positive trend that looks set to increase
-
Cancer care – the power of new technologies
Generally, new medicines and treatment approaches are offering renewed hope for cancer patients and the advent of innovative digital technologies is starting to disrupt clinical practice, presenting new ways of driving
-
Reaching the new influencers
Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)
-
Cancer in The Information Age: are we illuminated or inundated?
Personalised vs personal medicine. Data and information have already proved fruitful in the clinic, yielding the advent of personalised cancer medicine,.
-
No incentive for a cure
the health of motor neurons. The advent of these ‘regenerative medicines’ - often highly tailored to the patient’s specific genetic make-up - is a genuine revolution in healthcare.
More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.
Latest from PMHub
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
-
Training the next generation of biotech leaders
With the advent of personalised medicine, biotechs and academia are focusing their efforts on ensuring the manufacturing process can be both scaled up and reproduced.
-
Data Visualisation in Medical Communication
The advent of big data means that we now have access to unprecedented volumes of data, but we need tools to process and understand it.
-
Marketing strategy in complex environments
One example of this is in cystic fibrosis, and the advent of disease modifying agents specific towards certain genetic mutations ( Kalydeco, Orkambi).
-
A view from within #LucidLife
The advent of a significant birthday is an opportunity for reflection, and so I’ve been considering the journey that Lucid and I have been on. Lucid has always adopted a
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
Featured jobs
- Principal Health Economist - North-West
-
Negotiable
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Business Development Director – Health Education
-
excellent commission
-
Account Manager
-
Negotiable
-
Account Manager / Account Director
-
Competative
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Systematic Reviewer - Oxford
-
Negotiable
-
Business Director
-
Competitive Salary Offered
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
- Account Manager- Healthcare Advertising
-
Negotiable
- Account Manager- Healthcare Advertising
-
Negotiable
-
Account Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical (Scientific) Director
-
£120, 000 benefits
Subscribe to our email news alerts
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
- As May delays, industry warns again of ‘no-deal’ Brexit
- Clark Health Communications and Egg digital announce new collaboration
- Axovant drops last ‘legacy’ drug to focus on gene therapies
- Healthcare excellence celebrated at 2018 HSJ Awards
- Better together when buying medicines? Taking stock of the BeNeLuxA initiative
PMHub
Star
We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
